Valuation: Ondine Biomedical Inc.

Capitalization 71.73M 51.93M 44.36M 40.9M 38.6M 4.86B 73.55M 479M 188M 2.32B 195M 191M 8.29B P/E ratio 2023
-2.01x
P/E ratio 2024 -2.27x
Enterprise value 62.13M 44.98M 38.43M 35.43M 33.44M 4.21B 63.71M 415M 163M 2.01B 169M 165M 7.18B EV / Sales 2023
25.7x
EV / Sales 2024 26.6x
Free-Float
48.54%
Yield 2023 *
-
Yield 2024 -
1 day+2.27%
1 week+7.14%
Current month+4.65%
1 month+2.27%
3 months+40.62%
6 months-13.46%
Current year+28.57%
1 week 10.5
Extreme 10.5
12.51
1 month 10
Extreme 10
12.51
Current year 7.5
Extreme 7.5
12.51
1 year 7.5
Extreme 7.5
18.5
3 years 5
Extreme 5
20.4
5 years 5
Extreme 5
60
10 years 5
Extreme 5
60
Manager TitleAgeSince
Chief Executive Officer 64 2004-02-29
President 66 2009-01-05
Chief Operating Officer - -
Director TitleAgeSince
Chairman 64 2009-03-29
Director/Board Member 66 2009-01-05
Chairman 67 2021-12-06
Change 5d. change 1-year change 3-years change Capi.($)
+2.27%+7.14%+18.42%-31.82% 76.88M
+0.81%-0.38%-20.73%-2.42% 175B
+0.66%+2.40%+5.08%+9.65% 113B
+0.32%-0.45%+12.37%+91.14% 62.08B
+0.79%+5.15%+97.32%+105.16% 61.26B
+0.33%+0.57%-24.24%-39.01% 44.26B
+1.15%+10.97% - - 38.33B
+0.24%-0.16%-6.50%-45.54% 24.29B
+0.20%+2.58%+0.39%+20.56% 22.05B
+1.01%-1.37%-19.50%+13.06% 19.71B
Average +0.78%+1.54%+6.96%+13.42% 56.04B
Weighted average by Cap. +0.67%+0.75%+3.95%+20.38%

Financials

2023 2024
Net sales 1.2M 871K 744K 686K 647K 81.55M 1.23M 8.03M 3.16M 38.94M 3.27M 3.2M 139M 2.05M 1.48M 1.27M 1.17M 1.1M 139M 2.1M 13.69M 5.38M 66.33M 5.57M 5.45M 237M
Net income -14.41M -10.43M -8.91M -8.22M -7.76M -977M -14.78M -96.26M -37.84M -467M -39.15M -38.32M -1.67B -19.1M -13.83M -11.81M -10.89M -10.28M -1.29B -19.58M -128M -50.15M -618M -51.89M -50.79M -2.21B
Net Debt -2.44M -1.77M -1.51M -1.39M -1.31M -165M -2.5M -16.3M -6.41M -78.99M -6.63M -6.49M -282M -9.6M -6.95M -5.94M -5.47M -5.17M -651M -9.84M -64.11M -25.21M -311M -26.08M -25.53M -1.11B
Logo Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company. The Company is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. It also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.
Employees
18
Date Price Change Volume
26-04-14 11.25 p +2.27% 1,341,389
26-04-13 11.00 p 0.00% 1,402,903
26-04-10 11.00 p 0.00% 449,537
26-04-09 11.00 p 0.00% 281,232
26-04-08 11.00 p +4.76% 378,134

Annual profits - Rate of surprise